Device and method for compartmental vessel treatment

Information

  • Patent Grant
  • 11529500
  • Patent Number
    11,529,500
  • Date Filed
    Tuesday, January 7, 2020
    4 years ago
  • Date Issued
    Tuesday, December 20, 2022
    a year ago
Abstract
An angioplasty balloon having an elastic constraining structure that partially expands with the balloon so that, at maximum balloon inflation, the constraining structure forms a pattern of channels or “pillows” on the balloon.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention

The present invention relates to the field of medical methods and devices, more specifically to medical angioplasty balloon catheters and devices intended to deliver active substances to body tissue.


Angioplasty balloons are one of the most commonly used tools for the treatment of narrowed blood vessels. These balloons are typically cylindrical when inflated and have different lengths and diameters to conform to different vessel sizes. The balloons are located at the distal end of flexible catheters and delivered to a target site/lesion where they are inflated at high pressure, normally between 8-20 atmospheres, in order to overcome the resistance of the lesion and achieve luminal expansion. Such high pressure angioplasty is often associated with trauma to the vessel walls with a resulting high frequency of vessel dissection (30%-40%), abrupt closure of the treated vessel (5%-12%), and restenosis. Thus, when conventional angioplasty is used as a primary treatment for occluded vessels, restenosis can occur in about 50% of the cases. Therefore, in the vast majority of coronary treatments, angioplasty is used as an initial treatment followed by placement of a stents. Frequently, the stents are coated with drug and polymer requiring the patient to take anti platelet therapy for extended periods, possibly lifelong, to limit the risk of stent thrombosis or blood clots. Anti platelet therapy increases the risk of bleeding and is expensive. In addition, patient must stop the antiplatelet therapy before any surgical intervention, thus increasing the risk of sudden death and often precluding beneficial procedures.


Dissections in blood vessels treated by balloon angioplasty are very common. The dissection rate is estimated to be as high as 30% of all cases. Some of the dissections are severe and may require urgent surgery or placement of additional stents. In addition, dissection may contribute to poor long term clinical results and restenosis even if a stent is placed in the treated lesion. Dissections are usually attributed to several mechanisms occurring during balloon inflation including shear forces applied on the vessel walls as the balloon pleats unfold as well as the uneven balloon inflation which occurs as a result of the non-symmetric nature of the vascular disease. During inflation, the balloon diameter increases in the radial direction as the folded balloon unwraps. As the folded lobes of the balloon open, the layers slide over one another and apply tangential forces to the lesion and/or vessel wall which can abrade the lesion or vascular wall and in the worst instances cause dissections. As shown in FIGS. 1A-1C, a catheter 10 is initially located in a region of plaque (P) in a blood vessel (BV). A balloon 12 on the catheter 10 has folded lobes which unfold as the balloon is inflated, as shown in FIG. 1B. The layers of the folded lobes move in opposite directions, as shown by the arrows in FIG. 1B, with the upper exposed layer tending to slide across the surface of the lesion or if present, exposed vascular wall. Such unintended lateral movement of the balloon surface can occur until the balloon is fully inflated, as shown in FIG. 1C.


Uneven inflation results from the uneven nature of the disease in the vessel. Angioplasty balloons are commonly non-compliant or semi-compliant, and when semi-compliant balloons are inflated against an eccentric lesion, the balloon will follow the “path of least resistance” and its diameter will increase more in the less diseased sections of the vessel, often increasing trauma in these areas.


For these reasons, it would be desirable to provide improved balloons and inflation structures for angioplasty balloons used in vascular treatments. In particular, it would be desirable to provide angioplasty balloons having a reduced tendency to cause trauma and dissection in the blood vessel walls as the balloon is inflated by modulating the inflation characteristics of the balloon and provide a segmented compartmental dilatation with local areas of compliance. It would be further desirable if the reduced dissections could also reduce the risk of elastic recoil and abrupt reclosure which are associated with current angioplasty balloons and their use. It would be further desired if such improved angioplasty balloon structures were compatible with each of stents, drug-eluting stents, and drug coated balloons. These advantages would preferably be obtained without loss of the ability of the catheters to increase the luminal size and restore blood vessel in the patient being treated. At least some of these objectives will be met by the invention as described hereinafter.


2. Description of the Background Art

U.S. Pat. Nos. 6,245,040 and 5,735,816, show balloon catheters having elastic spiral restraints which form spiral indentations in the balloon when inflated. Other patents of interest include U.S. Pat. Nos. 7,708,748; 7,686,824; 5,863,284; 5,772,681; 5,643,210; and 5,987,661.


BRIEF SUMMARY OF THE INVENTION

The present invention comprises a device for angioplasty or dilatation of stenotic vessels and optionally for the delivery of active substance to the vessel walls. A balloon catheter is designed to modulate the inflation characteristics of the balloon to provide a segmented compartmental dilatation with local regions of compliance capable of conforming to the uneven nature of the vascular disease. The balloon catheter of the present invention includes a constraining structure (CS) located over a balloon on a distal end of the catheter. The CS serves to control and limit balloon inflation and modify balloon topography, typically by forming protruding regions (“pillows”) over the surface that cause local dilatation in a small region of the vessel independent of those formed by neighboring protruding regions. Such discrete protruding regions will each separately engage a segment of the lesion when the balloon is inflated so that the pressure and degree of balloon expansion applied against that segment is controlled and limited, thus reducing the risk of trauma while assuring that all segments of the lesion are adequately treated. The lesion can be uniformly treated along its length while excessive pressure against any one segment of the lesion can be reduced or avoided entirely. Such local dilatation avoids the “path of least resistance” phenomenon described above and allows local and non-uniform treatment for different sections or regions of the vessel, where the modified balloon topography minimizes trauma and injury of vessel wall as the balloon is inflated to the very high pressures associated with angioplasty. The CS also inhibits transfer of shear forces to the lesion and vessel wall as the balloon inflates and the wall layers open and slide laterally relative to the vessel wall. Conventional balloons present a continuous surface across the treated section of the vessel (sometimes as long as 200 mm to 300 mm in peripheral lesions) that leads to balloon deformation and uneven along the treated segment. Such an “aggregated dilatation” mechanism when applied to a diseased vessel having an uneven lesion geometry increases the probability of trauma and dissection. In contrast, the balloon of this invention provides for a more localized but balanced force distribution (e.g., as a result of the uniformly distributed protruding regions) along the length of the disease even when the disease varies significantly in size over its length.


In one embodiment of this invention, the CS is situated over the deflated and folded balloon and attached to a shaft of the catheter near a distal end of the balloon, near a proximal end of the balloon, or preferably both. The CS does not have to be attached to the balloon and can float over the folded balloon optionally having elastic covers at either or both ends (e.g., covers made of polymer). Upon balloon inflation, the CS expands to its maximum diameter and allows the balloon to further inflate through openings in the CS in a preselected pattern. Upon device deflation, the CS will elastically close to its original diameter.


In one embodiment of the invention as the balloon inflates, both the balloon and CS increase in diameter. The CS maximal open diameter, however, is smaller than fully inflated balloon diameter thus balloon continues to expand through the openings in the CS creating a series of protruding regions, typically in an orthogonal or diamond “quilted” pattern. The CS has a relatively small diameter before expansion and is capable of expanding due to inflation force applied by balloon expansion to a diameter smaller than that of the fully inflated balloon. The CS expansion is limited by its geometrical design.


The CS is designed to control balloon inflation by limiting and restricting balloon diameter across the treated segment in a way that will eliminate large diameter differences during the inflation process. Thus, when balloon pressure is increased, as is commonly done in order to overcome local narrowing, overstretching other parts of the treated lesion can be reduced or avoided entirely In addition, the CS can reduce or eliminate the transfer of tangential forces resulting from unfolding of the balloon against the vessel wall. The CS creates a network of crossing channels with protruding regions or “pillows” therebetween. The channels between the protruding regions prevent high radial stress buildup by providing stress relief regions between adjacent protruding regions. The stress relief regions can stretch or expand without being subjected to direct balloon surface contact thus minimizing trauma caused to vessel walls during inflation. In addition, the channels allow for plaque extrusion (redistribution) thus adding a new mechanism in addition to simple compression mechanism of conventional balloons.


In a first aspect, the present invention provides a system for performing angioplasty. The system includes a catheter shaft having an inflatable balloon at its distal end and a constraining structure disposed over the inflatable balloon. The constraining structure has a non-expanded configuration where it lies closely over or within folds of the balloon prior to inflation and an expanded configuration which is smaller than an unconstrained size of the balloon (when fully inflated) so that the structure restrains the balloon inflation along a plurality of crossing channel lines. By “crossing” channel lines, it is meant that the channels will intersect at a plurality of locations so that the channels comprise an intersecting matrix of interconnected channels. Individual channel lines may be oriented axially, circumferentially, or preferably will include channel lines with both axial and circumferential orientations where the axial channels intersect the circumferential channels. Alternatively, the channels could be formed as two or more counter wound helical channels that intersect to form diamond-shaped protruding regions.


In specific preferred embodiments, the constraining structure will comprise a plurality of circumferentially spaced-apart axial struts and a multiplicity of axially spaced-apart radially expandable rings attached to the axial struts. The rings are joined to the struts at intersecting angles, preferably in the range from about 75° to 105°. In particularly preferred embodiments, the intersecting angles will be 90°. The axial struts will be coupled to the catheter on both a distal side of the balloon and on a proximal side of the balloon. In some embodiments, at least one of the distal strut ends and the proximal strut ends will be free to translate axially over the catheter shaft as the balloon is inflated (to accommodate foreshortening which would otherwise occur). Alternatively, the individual struts may be fixedly attached to the catheter shaft on both the proximal and distal side of the balloon where the struts are elastic or otherwise stretchable in tension so that they will elongate as the balloon is inflated. For example, axial struts could be composed of an elastomer or other elastic material which allows elongation. More typically, the axial struts would include features, such as zig-zags, S-shaped links, coil springs, or the like, which would accommodate elongation (if needed) when either or both of the strut ends are attached to the catheter shaft.


The radially expandable rings will also be formed so that they can stretch or elongate to increase in diameter as the balloon is inflated in the ring. The expandable rings could be formed from inherently elastic materials, such as stretchable polymers or the like, but more typically will be formed with expansible features which allow the ring to expand when the balloon is inflated. The expandable features can be the same as with the axial struts, including zig-zags, S-shaped curves, coils, and the like. In all cases, it is necessary that the rings have an maximum diameter beyond which they will not further increase in size as the balloon is inflated. When the rings are formed with expandable features, the maximum ring expansion will occur when these features are fully elongated. If an elastomeric or other material is used to form the rings, non-distensible tethers or other expansion limits can be built into the rings so that they do not exceed their desired maximum diameter.


The balloons may also be coated or otherwise adapted to deliver drugs. Techniques for coating balloons with drugs are well described in the patent literature. See, for example, U.S. Pat. No. 7,750,041; US2010/02280228; US2010/0278744; and US2008/0102034, the full disclosures of which are incorporated herein by reference.


In a second aspect, the present invention provides a method for treating a lesion in a blood vessel. The method comprises inflating a balloon within the blood vessel where the balloon is constrained along a plurality of crossing channel lines, typically axial and/or circumferential channel lines which intersect and cross each other. The channel lines create a number of isolated protruding regions in the balloon, where the protruding regions contact the lesion while the channel lines are recessed away from the vessel wall. “Recessed” means that the bottom or trough of the channel line will be positioned radially closer to the axis of the catheter than is the inflated surface of the balloon. In many cases, the bottoms of the channels will not contact the lesion or blood vessel wall. In other cases, however, particularly when the plaque or thrombosis being extruded, the channels may fill with the lesion material while providing the benefits of stress relief described above since the bottoms of the channels will remain spaced radially inwardly from the blood vessel wall.


The balloon will typically be composed of a non-distensible or semi-compliant material so that it may be inflated at relatively high pressures, typically in the range from 10 atmospheres to 25 atmospheres, without over expanding within the blood vessel. Thus, both the balloon (when non-distensible) and the constraining structure will have maximum diameters when the balloon is fully inflated where the difference in the maximum diameters defines the depth of the channels which are formed in the balloon surface. The protruding regions will often have similar sizes (±50% of area engaging the lesion) and will be uniformly distributed over the balloon surface. The balloons may be used for angioplasty, without subsequent stent delivery and/or drug delivery. Alternatively, the balloons may be used for expanding a stent, including both drug-coated stents and uncoated stents. Finally, the balloons may themselves be coated with drug in order to transfer drug to the lesion or vessel wall during the treatment.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A to 1C show a cross-section of the stages of unwrapping of conventional balloon inflation in a stenotic blood vessel.



FIGS. 2A, 2B1 and 2B2 show a constraining structure located on a balloon prior to inflation (FIG. 2B1) and after inflation (FIGS. 2A and 2B2).



FIGS. 3A and 3B illustrate a first exemplary ring structure where the ring segments between adjacent axial struts are formed in a zig-zag pattern.



FIGS. 4A and 4B illustrate a first exemplary ring structure where the ring segments between adjacent axial struts are formed in a S-shaped pattern.



FIGS. 5A and 5B illustrate a first exemplary ring structure where the ring segments between adjacent axial struts are formed as a coil spring.



FIGS. 6A to 6C show a cross-section of the dilatation device in this invention during three stages of inflation with the balloon unwrapping within the constraining device.



FIGS. 7A and 7B show finite element analyses of the vessel trauma of a conventional balloon and the device described in this invention.





DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a device for treating of diseased, blocked, occluded or stenotic lumens in the body, typically blood vessels including both arteries and veins, and more typically coronary and peripheral arteries. This device dilates occluded vessels while minimizing trauma to the lesion and luminal wall and reducing the risk of vessel trauma and injury. By placing an “elastic” constraining structure (CS) over a balloon of a balloon catheter, inflation of the balloon is controlled during balloon inflation and refolding of the balloon is aided as the balloon is deflated. The CS is designed to expand to a diameter smaller than the maximal diameter of the balloon when fully inflated. The CS structure applies radial resistance to inflation and is thus able to constrain the balloon and distribute or buffer the internal high pressure applied by the balloon to the luminal wall thus providing a controlled and less traumatic dilation process. The balloon which is typically formed from a non-distensible material such as a polyamide or a polyether block amide, will preferably be non-distensible or semi-compliant with a stretchability below 10% within typical inflation pressure ranges and a fully inflated size sufficiently large so that regions protrude through passages in the CS to form protruding regions which engage and dilate the lesion.


The CS can be coupled or otherwise connected to the catheter shaft on the distal side and/or the proximal side of the balloon. Alternatively, the CS can float over the balloon without fixed attachment using simple covers or constraints, and the CS is preferably designed to maintain its length during expansion of the balloon to limit relative axial movement between the CS and the balloon. The CS can be fabricated from various materials using suitable processes and designs. The CS can be made from metal, preferably an elastic metal such as a nickel-titanium alloy (Nitinol®) and/or from a variety of polymers (e.g., Nylon). For example, the CS can be constructed from wires or can be laser cut from a tube, sheath or other forms of materials.


In a preferred embodiment of this invention, the CS structure is located on the balloon and is expanded during balloon inflation. The CS expands to a smaller diameter than the balloon thus constricting balloon inflation within a cylindrical cage. Parts of the balloon, however, keep expanding through openings in the case of the CS creating controlled dilatation pattern and reducing or eliminating shear forces.


Once the CS reaches its maximum diameter (which is smaller than the maximum inflated balloon diameter), the balloon continues to inflate through openings in the CS creating a topography of protruding regions (hills) and channels (valleys) at the surface of the device, where the pattern of channels is defined by the geometry of the CS. The CS contributes to a controlled dilation process avoiding over expansion and minimizing the shear forces and uniform high pressure applied on the vessel wall as will be described in greater detail below with reference to FIGS. 6A-6C and 7.


Referring now to FIGS. 2A, 2B1 and 2B2, an exemplary constraining structure 14 constructed in accordance with the principles of the present invention comprises a plurality of axial struts 16 and axially spaced-apart radially expandable rings 18. When the balloon 12 and the catheter 10 is in its non-inflated state (as illustrated in FIG. 2B1), the balloon is folded with a number of overlapping lobes, as best seen in FIG. 6A (discussed below). The constraining structure 14 has a generally cylindrical geometry with a diameter just large enough to cover the deflated balloon 12.


As the balloon 12 is inflated, as illustrated in FIGS. 2A and 2B2, the radially expandable rings 18 expand in response to the force of the balloon. The rings will be structured, however, so that they reach a maximum diameter beyond which they will no longer radially expand regardless of the continued inflation or expansion of the balloon. As the axial struts 16 are attached or otherwise coupled to the radially expandable rings 18, the radially outward travel of the struts is also limited to a distance defined by the maximum diameter of the rings. Thus, as the balloon will have a fully inflated diameter which is larger than that of the maximum diameter of the radially expandable rings 18, when the balloon is fully inflated a plurality of axial and circumferential channels 20 and 22, respectively, will be formed in the balloon surface. A plurality of protruding regions 24 (as seen in FIG. 2B2) are defined in the openings or in interstices between the adjacent axial struts 16 and radially expandable rings 18. It is these protruding regions 24 which provide the benefits of the present invention as described above.


The axial struts 16 and radially expandable rings 18 of the constraining structure 14 are illustrated as simple straight beams or elements, it will be appreciated that they need to have some elasticity or stretchability in order to accommodate the radial expansion of the balloon and the radial increase in size of the rings. While the axial struts 14 need only be flexible since they can be free to slide along the catheter shaft 26 at either or both of the proximal and distal ends, the rings 18 must have the ability to elongate in the circumferential dimension as the balloon increases in diameter, although the rings will have a maximum diameter beyond which they will not expand, as discussed above. Most simply, the axial struts 16 and/or the radial expansion rings 18 may be formed from an elastic material which is capable of elongating under a tensile force, such as an elastomeric polymer, a coil spring, or the like. If such materials and/or structures are used with the radially expandable rings, however, there must also be a separate non-distensible or non-stretchable component which provides for the radial expansion limit.


Alternatively, the axial struts 16 and/or the radially expansible rings 18 may be formed from a generally non-stretchable material, typically a metal such as a nickel-titanium alloy as noted above, and be provided with features or patterns which allow for elongation under a tensile force. For example, as illustrated in FIGS. 3A and 3B, the radially expandable rings 18 could be formed in a zig-zag pattern so that they can elongate from a shortened configuration, as shown in FIG. 3A, to a fully elongated configuration, as shown in FIG. 3B. Although not illustrated, it will be appreciated that the axial struts could employ the same geometric features allowing for axial elongation. Shown in FIGS. 4A and 4B, the rings 18 could be provided with S-shaped or serpentine structures which allow for elongation from a shortened configuration (FIG. 4A) to a fully elongated configuration (FIG. 4B) corresponding to the fully expanded diameter configuration shown in FIGS. 2A and 2B2. Alternatively, the rings 18 could be provided with a coil configuration, as shown in FIGS. 5A and 5B, where the coil will assume a shortened configuration when the ring is at its minimum diameter, as shown in FIG. 5A, and will stretch to accommodate a fully expanded configuration, as shown in FIG. 5B. The coil springs, however, like the elastic polymer embodiments described above will in most instances require a separate element or component to prevent expansion beyond the desired maximum limit.


Referring now to FIGS. 6A through 6C, the catheter 10 carrying the balloon 12 and constraining structure 14 is introduced to a region of plaque P and a blood vessel BV in a generally conventional manner. Once the balloon 12 and constraining structure 14 are at the target location, the balloon is inflated, causing the constraining structure 14 to radially expand until it reaches a maximum diameter, as shown in FIG. 6B. Once it has reached its maximum diameter, the constraining structure 14 will no longer expand, but portions of the balloon 12 which are located in the open regions between adjacent axial struts and radially expandable rings will continue to expand until reaching their maximum expansion, as shown in FIG. 6C, where the fully formed protruding regions 24 are present. As the balloon 12 will typically be formed from a non-distensible material, as noted above, once the maximum balloon size has been reached further balloon inflation will not significantly increase the balloon size.



FIGS. 7A and 7B show finite element analyses of the forces applied on the vessel wall comparing a conventional balloon (FIG. 7A) with the device of the present invention (FIG. 7B). The conventional balloon displays uniform high strains in contrast to the balloon of this invention which displays stretching in the areas where the tissue is free from contact with the balloon. The uniform balloon pressure is replaced with an alternating pressure pattern that reduces vessel trauma.


The present invention can be utilized to deliver various agents or active substances particularly (but not limited to) those suitable for treating vascular and other luminal conditions such as antiproliferative and antimitotic agents (such as paclitaxel and sirolimus) other substances can include antibiotics, antiplatelet agents hormones and more.


The active substance can be placed in various designs or techniques such as directly coated on the balloon surface, the CS or both. It can be embedded in a matrix/carrier placed on the balloon or the CS or both. The combination of low trauma dilatation with release of active agent can be superior to drug eluting stents for some portions of the population by minimizing the need for a permanent implant yet providing good long term results.


In one embodiment the balloon surface is coated with drug. Upon balloon inflation, the protruding regions formed in the balloon external surface coated with drug engage the vessel wall and compress the drug into the wall to facilitate efficient drug delivery to the treated site.


Drug delivery can be facilitated using many different design methods including but not limited to coating the balloon, coating the CS structure or both. Coating with a drug directly or using a carrier in a form of a matrix or microcapsules.


While the above is a complete description of the preferred embodiment of the invention, various alternatives, modifications, additions and substitutions are possible without departing from the scope thereof, which is defined by the claims.

Claims
  • 1. A balloon catheter comprising: a catheter shaft;a balloon on the catheter shaft; anda constraining structure disposed over the balloon, the constraining structure fixedly attached to the catheter shaft distal of the balloon and/or proximal of the balloon to prevent detachment of the constraining structure from the catheter shaft, the constraining structure comprising a plurality of openings;wherein the constraining structure is configured to transition between an unexpanded configuration and an expanded configuration;wherein inflation of the balloon expands the constraining structure to the expanded configuration with a plurality of isolated balloon regions protruding from the plurality of openings, the plurality of isolated balloon regions configured to contact a wall of a blood vessel with the constraining structure displaced from the wall of the blood vessel.
  • 2. The balloon catheter of claim 1, wherein the constraining structure is fixedly attached to the catheter shaft distal of the balloon and proximal of the balloon.
  • 3. The balloon catheter of claim 1, wherein, prior to inflation of the balloon, the balloon is folded beneath the constraining structure.
  • 4. The balloon catheter of claim 1, wherein the balloon is coated with a drug.
  • 5. The balloon catheter of claim 1, wherein the constraining structure is coated with a drug.
  • 6. The balloon catheter of claim 1, wherein the plurality of isolated balloon regions are uniformly distributed over a surface of the balloon.
  • 7. The balloon catheter of claim 1, wherein the constraining structure comprises a polymer material.
  • 8. The balloon catheter of claim 1, wherein the constraining structure comprises an elastic material.
  • 9. The balloon catheter of claim 1, wherein the balloon comprises a semi-compliant material.
  • 10. The balloon catheter of claim 1, wherein the plurality of isolated balloon regions are diamond shaped.
  • 11. A balloon catheter comprising: a catheter shaft;a balloon on the catheter shaft; anda constraining structure disposed over the balloon, the constraining structure fixedly attached to the catheter shaft distal of the balloon and/or proximal of the balloon to prevent detachment of the constraining structure from the catheter shaft;wherein inflation of the balloon expands the constraining structure to create a plurality of isolated balloon regions separated by a plurality of intersecting channels formed by the constraining structure;wherein the plurality of isolated balloon regions are configured to contact a wall of a blood vessel with the constraining structure displaced from the wall of the blood vessel.
  • 12. The balloon catheter of claim 11, wherein the plurality of intersecting channels comprise two or more helical channels.
  • 13. The balloon catheter of claim 11, wherein the plurality of intersecting channels comprise a plurality of axially oriented channels.
  • 14. The balloon catheter of claim 11, wherein the plurality of intersecting channels comprise a plurality of circumferentially oriented channels.
  • 15. The balloon catheter of claim 11, wherein the plurality of intersecting channels comprise a plurality of axially-oriented channels intersecting a plurality of circumferentially oriented channels.
  • 16. The balloon catheter of claim 11, wherein at least some of the plurality of intersecting channels intersect to form an angle between 75 degrees and 105 degrees, inclusive.
  • 17. The balloon catheter of claim 11, wherein, prior to inflation of the balloon, the balloon is folded beneath the constraining structure.
  • 18. The balloon catheter of claim 11, wherein the balloon is coated with a drug.
  • 19. The balloon catheter of claim 11, wherein the constraining structure is coated with a drug.
  • 20. The balloon catheter of claim 11, wherein the balloon comprises a semi-compliant material.
Parent Case Info

This application claims the benefit of Provisional Application No. 61/313,600, filed on Mar. 12, 2010, the full disclosure of which is incorporated herein by reference.

US Referenced Citations (197)
Number Name Date Kind
2701559 Cooper Feb 1955 A
2854983 Baskin Oct 1958 A
3045677 Wallace Jul 1962 A
3467101 Fogarty et al. Sep 1969 A
3825013 Craven Jul 1974 A
4327736 Inoue May 1982 A
4456011 Warnecke Jun 1984 A
4483340 Fogarty et al. Nov 1984 A
4637396 Cook Jan 1987 A
4723549 Wholey et al. Feb 1988 A
4796629 Grayzel Jan 1989 A
4921484 Hillstead May 1990 A
4976711 Parins et al. Dec 1990 A
4998539 Delsanti Mar 1991 A
5071407 Porter et al. Dec 1991 A
5100386 Inoue Mar 1992 A
5133732 Wilkor Jul 1992 A
5176693 Pannek Jan 1993 A
5181911 Shturman Jan 1993 A
5190058 Jones et al. Mar 1993 A
5196024 Barath Mar 1993 A
5222971 Willard et al. Jun 1993 A
5224945 Pannek, Jr. Jul 1993 A
5263963 Garrison et al. Nov 1993 A
5308356 Blackshear, Jr. et al. May 1994 A
5320634 Vigil et al. Jun 1994 A
5336178 Kaplan Aug 1994 A
5336234 Vigil et al. Aug 1994 A
5344419 Spears Sep 1994 A
5449372 Schmaltz et al. Sep 1995 A
5456666 Campbell et al. Oct 1995 A
5456667 Ham et al. Oct 1995 A
5460607 Miyata et al. Oct 1995 A
5484411 Inderbitzen et al. Jan 1996 A
5501694 Ressemann et al. Mar 1996 A
5527282 Segal Jun 1996 A
5556408 Farhat Sep 1996 A
5562620 Klein et al. Oct 1996 A
5571086 Kaplan et al. Nov 1996 A
5607442 Fischell et al. Mar 1997 A
5609574 Kaplan et al. Mar 1997 A
5616149 Barath Apr 1997 A
5620457 Pinchasik et al. Apr 1997 A
5628746 Clayman May 1997 A
5628755 Heller et al. May 1997 A
5643210 Iacob Jul 1997 A
5643312 Fischell et al. Jul 1997 A
5695469 Segal Dec 1997 A
5702410 Klunder et al. Dec 1997 A
5713863 Vigil et al. Feb 1998 A
5730698 Fischell et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5735816 Lieber et al. Apr 1998 A
5755781 Jayaraman May 1998 A
5772681 Leoni Jun 1998 A
5776181 Lee et al. Jul 1998 A
5797935 Barath Aug 1998 A
5810767 Klein Sep 1998 A
5827321 Roubin et al. Oct 1998 A
5863284 Klein Jan 1999 A
5868708 Hart et al. Feb 1999 A
5868719 Tsukernik Feb 1999 A
5868779 Ruiz Feb 1999 A
5868783 Tower Feb 1999 A
5869284 Cao et al. Feb 1999 A
5904679 Clayman May 1999 A
5906639 Rudnick et al. May 1999 A
5919200 Stambaugh et al. Jul 1999 A
5961490 Adams Oct 1999 A
5967984 Chu et al. Oct 1999 A
5987661 Peterson Nov 1999 A
6013055 Bampos et al. Jan 2000 A
6036689 Tu et al. Mar 2000 A
6036708 Sciver Mar 2000 A
6053913 Tu et al. Apr 2000 A
6059810 Brown et al. May 2000 A
6059811 Pinchasik et al. May 2000 A
6077298 Tu et al. Jun 2000 A
6102904 Vigil et al. Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6129706 Janacek Oct 2000 A
6156265 Sugimoto Dec 2000 A
6190403 Fischell et al. Feb 2001 B1
6206910 Berry et al. Mar 2001 B1
6217608 Penn et al. Apr 2001 B1
6235043 Reiley et al. May 2001 B1
6241762 Shanley Jun 2001 B1
6245040 Inderbitzen et al. Jun 2001 B1
6258099 Mareiro et al. Jul 2001 B1
6261319 Kveen et al. Jul 2001 B1
6309414 Rolando et al. Oct 2001 B1
6319251 Tu et al. Nov 2001 B1
6334871 Dor et al. Jan 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6416539 Hassdenteufel Jul 2002 B1
6454775 Demarais et al. Sep 2002 B1
6540722 Boyle et al. Apr 2003 B1
6605107 Klein Aug 2003 B1
6616678 Nishtala et al. Sep 2003 B2
6626861 Hart et al. Sep 2003 B1
6652548 Evans et al. Nov 2003 B2
6656351 Boyle Dec 2003 B2
6695813 Boyle et al. Feb 2004 B1
6702834 Boylan et al. Mar 2004 B1
6939320 Lennox Sep 2005 B2
6942680 Grayzel et al. Sep 2005 B2
7156869 Pacetti Jan 2007 B1
7186237 Meyer et al. Mar 2007 B2
7357813 Burgermeister Apr 2008 B2
7686824 Konstantino et al. Mar 2010 B2
7691119 Farnan Apr 2010 B2
7708748 Weisenburgh, II et al. May 2010 B2
7753907 DiMatteo et al. Jul 2010 B2
7803149 Bates et al. Sep 2010 B2
7931663 Farnan et al. Apr 2011 B2
8172793 Bates et al. May 2012 B2
8257305 Speck et al. Sep 2012 B2
8348987 Eaton Jan 2013 B2
8388573 Cox Mar 2013 B1
8439868 Speck et al. May 2013 B2
9179936 Feld et al. Nov 2015 B2
9199066 Konstantino Dec 2015 B2
9216033 Feld et al. Dec 2015 B2
9375328 Farnan Jun 2016 B2
9415140 Speck Aug 2016 B2
9649476 Speck et al. May 2017 B2
10220193 Feld et al. Mar 2019 B2
10232148 Konstantino et al. Mar 2019 B2
10524825 Feld et al. Jan 2020 B2
10549077 Konstantino Feb 2020 B2
11000680 Konstantino et al. May 2021 B2
11234843 Feld et al. Feb 2022 B2
20020010489 Grayzel et al. Jan 2002 A1
20030023200 Barbut et al. Jan 2003 A1
20030040790 Furst Feb 2003 A1
20030065354 Boyle Apr 2003 A1
20030078606 Lafontaine et al. Apr 2003 A1
20030114915 Mareiro et al. Jun 2003 A1
20030114921 Yoon Jun 2003 A1
20030120303 Boyle et al. Jun 2003 A1
20030144726 Majercak et al. Jul 2003 A1
20030153870 Meyer et al. Aug 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20030212449 Cox Nov 2003 A1
20040034384 Fukaya Feb 2004 A1
20040073284 Bates et al. Apr 2004 A1
20040111108 Farnan Jun 2004 A1
20040143287 Konstantino et al. Jul 2004 A1
20040210235 Deshmukh Oct 2004 A1
20040210299 Rogers et al. Oct 2004 A1
20040230293 Yip et al. Nov 2004 A1
20050021071 Konstantino et al. Jan 2005 A1
20050021130 Kveen et al. Jan 2005 A1
20050049677 Farnan Mar 2005 A1
20050125053 Yachia et al. Jun 2005 A1
20050271844 Mapes et al. Dec 2005 A1
20060008606 Horn et al. Jan 2006 A1
20060015133 Grayzel et al. Jan 2006 A1
20060085025 Farnan et al. Apr 2006 A1
20060085058 Rosenthal et al. Apr 2006 A1
20060149308 Melsheimer et al. Jul 2006 A1
20060259005 Konstantino et al. Nov 2006 A1
20060271093 Holman et al. Nov 2006 A1
20070073376 Krolik et al. Mar 2007 A1
20070173923 Savage et al. Jul 2007 A1
20080255508 Wang Oct 2008 A1
20090036964 Heringes et al. Feb 2009 A1
20090038752 Weng et al. Feb 2009 A1
20090105686 Snow et al. Apr 2009 A1
20090192453 Wesselman Jul 2009 A1
20090227949 Knapp et al. Sep 2009 A1
20090240270 Schneider et al. Sep 2009 A1
20090319023 Hildebrand et al. Dec 2009 A1
20100042121 Schnieder et al. Feb 2010 A1
20100234875 Allex et al. Sep 2010 A1
20100241215 Hansen et al. Sep 2010 A1
20100331809 Sandhu et al. Dec 2010 A1
20110066225 Trollsas et al. Mar 2011 A1
20110071616 Clarke et al. Mar 2011 A1
20110152905 Eaton Jun 2011 A1
20110172698 Davies et al. Jul 2011 A1
20120059401 Konstantino et al. Mar 2012 A1
20120083733 Chappa Apr 2012 A1
20120245607 Gershony et al. Sep 2012 A1
20130046237 Speck et al. Feb 2013 A1
20130116655 Bacino et al. May 2013 A1
20130190725 Pacetti et al. Jul 2013 A1
20130211381 Feld Aug 2013 A1
20140276406 Campbell et al. Sep 2014 A1
20150209556 Timothy Jul 2015 A1
20160100964 Feld et al. Apr 2016 A1
20190151627 Konstantino et al. May 2019 A1
20190151631 Feld et al. May 2019 A1
20200139093 Feld et al. May 2020 A1
20210128891 Konstantino et al. May 2021 A1
20210402160 Konstantino et al. Dec 2021 A1
20220168120 Feld et al. Jun 2022 A1
Foreign Referenced Citations (18)
Number Date Country
1568165 Jan 2005 CN
0 565 796 Oct 1993 EP
0 623 315 Nov 1994 EP
0 832 608 Apr 1998 EP
1 042 997 Oct 2000 EP
2 035 291 Mar 2009 EP
2005-508709 Apr 2005 JP
2014-528809 Oct 2014 JP
WO 9805377 Feb 1998 WO
WO 9850101 Nov 1998 WO
WO 0057815 Oct 2000 WO
WO 2002068011 Sep 2002 WO
WO 2003041760 May 2003 WO
WO 2005020855 Mar 2005 WO
WO 2011112863 Sep 2011 WO
WO 2013066566 May 2013 WO
WO 2013114201 Aug 2013 WO
WO 2013119735 Aug 2013 WO
Non-Patent Literature Citations (6)
Entry
AngioSculpt XL PT Scoring Balloon Catheter Brochure, AngioScore, Inc., Rev. C, May 2013.
Bearing Works, (PTFE) Polytetrafluoroethylene material specifications sheet, available online Feb. 11, 2018 at https://www.bearingworks.com/uploaded-assets/pdfs/retainers/ptfe-datasheet.pdf; printed Feb. 21, 2018, in 2 pages.
Brydson, J.A., “Plastics Materials—Sixth Edition,” 1995, p. 510, available in part online from https://books.google.com/books?id=wmohBQAAQBAJ&lpg=PA510&ots=G_4Q-OMpB4&dq=young's%20modulus%20of%20PEBAx&pg=PA510#v=onepage&q=young's%20modulus%20of%20PEBAx&f=false; printed on May 5, 2017.
Kadish, A., et al. “Mapping of Atrial Activation With a Noncontact, Multielectrode Catheter in Dogs,” Circulation: Journal of the American Heart Association, (Apr. 1999) 99: 1906-1913.
International Search Report for Appl. No. PCT/US2011/027982 dated May 6, 2011 in 3 pages.
“Materials Data Book,” Cambridge University Engineering Department, 2003, pp. 1-41.
Related Publications (1)
Number Date Country
20200215311 A1 Jul 2020 US
Provisional Applications (1)
Number Date Country
61313600 Mar 2010 US
Continuations (2)
Number Date Country
Parent 14952728 Nov 2015 US
Child 16736633 US
Parent 13044425 Mar 2011 US
Child 14952728 US